Atherosclerosis: PCSK9 inhibition reduces cardiovascular events in high-risk patients
- PMID: 28397846
- DOI: 10.1038/nrcardio.2017.40
Atherosclerosis: PCSK9 inhibition reduces cardiovascular events in high-risk patients
Comment on
-
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17. N Engl J Med. 2017. PMID: 28304224 Clinical Trial.
Similar articles
-
Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.J Am Coll Cardiol. 2013 Oct 15;62(16):1401-8. doi: 10.1016/j.jacc.2013.07.056. Epub 2013 Aug 21. J Am Coll Cardiol. 2013. PMID: 23973703 Review.
-
PCSK9: A key factor modulating atherosclerosis.J Atheroscler Thromb. 2015;22(3):221-30. doi: 10.5551/jat.27615. Epub 2014 Nov 18. J Atheroscler Thromb. 2015. PMID: 25410128 Review.
-
Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).Basic Res Cardiol. 2015 Mar;110(2):4. doi: 10.1007/s00395-015-0463-z. Epub 2015 Jan 20. Basic Res Cardiol. 2015. PMID: 25600226 Free PMC article. Review.
-
Understanding PCSK9 and anti-PCSK9 therapies.J Clin Lipidol. 2015 Mar-Apr;9(2):170-86. doi: 10.1016/j.jacl.2015.01.001. Epub 2015 Jan 13. J Clin Lipidol. 2015. PMID: 25911073 Review.
-
Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice.Circulation. 2012 Feb 21;125(7):894-901. doi: 10.1161/CIRCULATIONAHA.111.057406. Epub 2012 Jan 18. Circulation. 2012. PMID: 22261195
References
-
- N Engl J Med. 2017 Mar 17;:null - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous